Impact BioMedical Inc. recently amended its strategic merger agreement with Dr Ashleys Limited, extending key deadlines and addressing governance provisions related to loan agreements. This maneuver comes at a time of acute liquidity pressure, with the company operating at a net loss and exhibiting a fragile current ratio. The business model centers on pharmaceutical innovation via mergers and equity restructuring, positioning the combined entity to leverage new intellectual property and market channels. However, substantial financial risks and operational execution hurdles remain critical to monitor as the merger progresses toward completion.